Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Overall Survival
100%
Head and Neck Squamous Cell Carcinoma
92%
Metastatic Breast Cancer
92%
Breast Cancer
90%
Malignant Neoplasm
74%
Neoplasm
73%
Hormone Receptor
54%
Progression Free Survival
53%
Immune Checkpoint Inhibitor
46%
Palbociclib
46%
Gamma Urogastrone
36%
Hormone Therapy
33%
Capecitabine
32%
Abdominal Cancer
31%
Premenopause
30%
Cisplatin
29%
Squamous Cell Carcinoma
27%
Gefitinib
27%
Stomach Adenocarcinoma
27%
Non Small Cell Lung Cancer
27%
BRCA1
27%
Disease Free Survival
26%
Acute Myeloid Leukemia
25%
Induction Chemotherapy
25%
Germ Cell
24%
Triple Negative Breast Cancer
24%
Epidermal Growth Factor Receptor 2
23%
Neck
23%
Lymph Node Metastasis
22%
Metastatic Carcinoma
21%
Cancer Cell
21%
Nintedanib
20%
Hazard Ratio
20%
Combination Therapy
20%
Trastuzumab
20%
Breast Carcinoma
19%
Phase II Trials
18%
Regulatory T Cell
18%
Germinoma
18%
Endodermal Sinus Tumor
18%
Organizing Pneumonia
18%
Spindle Cell Sarcoma
18%
Rheumatoid Arthritis
18%
Supraclavicular Lymph Node
18%
Salivary Gland Cancer
18%
Etanercept
18%
Graft Versus Host Reaction
18%
Retrospective Cohort Study
18%
T Lymphocyte
18%
Inflammatory Arthritis
18%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
75%
Metastatic Breast Cancer
64%
Overall Survival
50%
Breast Cancer
45%
Progression Free Survival
41%
Head and Neck Squamous Cell Carcinoma
37%
Monotherapy
37%
Chemotherapy Regimens
36%
Tamoxifen
31%
Capecitabine
29%
Neoplasm
29%
Phase II Trials
27%
Immune Checkpoint Inhibitor
27%
Catenin
27%
Ramucirumab
27%
Paclitaxel
27%
Gefitinib
27%
Non Small Cell Lung Cancer
27%
Hormone Receptor
26%
Palbociclib
23%
Triple Negative Breast Cancer
20%
Fluorouracil
20%
Biological Marker
18%
Imatinib
18%
Nintedanib
18%
Hepatotoxicity
18%
Transdermal
18%
Duragesic
18%
Chronic Myeloid Leukemia
18%
Tolerability
18%
Erlotinib
18%
Wernicke's Encephalopathy
18%
Gemcitabine
18%
Rheumatoid Arthritis
18%
Etanercept
18%
Inflammatory Arthritis
18%
Salivary Gland Cancer
18%
Adverse Event
17%
Neutropenia
17%
Gamma Urogastrone
15%
Taxane
13%
Anthracycline
13%
Survival Rate
12%
Abdominal Cancer
11%
Combination Therapy
11%
Trastuzumab
11%
Prothrombin
10%
Cohort Study
9%
Biliary Tract Cancer
9%
Atezolizumab
9%
Immunology and Microbiology
Overall Survival
61%
Neck
37%
CD34
37%
Squamous Cell
37%
Progression Free Survival
35%
Regulatory T Cell
27%
Immune Checkpoint Inhibitor
27%
Myeloid
23%
T Cell
19%
Etanercept
18%
Graft-Versus-Host Disease
18%
Adherent Cell
18%
Umbilical Cord Blood
18%
Cerebrospinal Fluid
18%
Inflammatory Arthritis
18%
Atezolizumab
18%
Autologous Peripheral Blood Stem Cell Transplantation
18%
Disease Free Survival
16%
Gamma Urogastrone
14%
Gonadotropin-Releasing Hormone
13%
Premenopause
13%
CD44
11%
Natural Killer Cell
11%
Nivolumab
10%
Endothelial Cells
9%
Tumor-Infiltrating Lymphocytes
9%
Tumor Necrosis Factor Alpha
9%
Hematopoietic Stem Cell Transplantation
9%
Tumor-Associated Macrophage
9%
Tumor Volume
9%
Gene Expression Assay
9%
Trastuzumab
9%
Hepatobiliary System
9%
Phosphotransferase
8%
Kinase
8%
Survival Rate
8%
Lymphocyte
7%
Programmed Death 1 Ligand 1
7%
Neutrophil
7%
Ciclosporin
7%
Cell Count
7%
Interferon Type I
7%
Propensity Score Matching
6%
Programmed Death-Ligand 1
6%
X-Ray Computed Tomography
6%
CD4
6%
Arm
6%
Aromatase
5%
Macrophage
5%